Clinical Trial Update: Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of durvalumab and tremelimumab for hepatocellular carcinoma in patients listed for liver transplantation is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Hepatocellular Carcinoma
• Portal Hypertension

Drugs mentioned

• Imfinzi (durvalumab) (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Davendra Sohal | Conditions: Hepatocellular Carcinoma, Cirrhosis | Phase 2 | Status: ACTIVE_NOT_RECRUITING